Clinical Trial Update: Observational Study of Muscle Invasive Urothelial Carcinoma Participants Treated With Adjuvant Nivolumab in France

View source ↗

Summary

An observational study of muscle-invasive urothelial carcinoma patients treated with adjuvant nivolumab in France has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Urothelial Carcinoma

Drugs mentioned

• nivolumab (Opdivo) (nivolumab)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Urothelial Carcinoma | Status: TERMINATED